Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A third of patients taking neoadjuvant Opdivo for inoperable advanced liver cancer had complete responses in an early analysis.
Brain fog can have many causes including cancer itself and different types of treatment.
Atezolizumab plus chemotherapy delays disease progression in people with metastatic triple-negative breast cancer.
Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.
A high-fiber diet may help checkpoint medications work better—but probiotic supplements could interfere with response.
Lung cancer advocate Don Stranathan takes on the No. 1 cancer killer.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
NKTR-214 plus Opdivo as first-line therapy had an overall response rate of 48 percent.
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
Changes include approval of new drug therapies, using existing drugs more effectively and revising protocols to reduce toxic side effects.
Seventy percent of liver cancer patients had either a partial response or stable disease.
As more patients respond well to these emerging therapies, the rules for treating late-stage patients will need to be rewritten.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.